Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Pharmacokinetics of hydroxycamptothecin nanosuspensions in rats.

Wang L, Hua HY, Liu WJ, Zhao YX, Zhang ZZ.

Pharmazie. 2011 Jul;66(7):547-8.

PMID:
21812333
2.
3.

Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin in rats.

Chen J, Ping Q, Guo J, Liu M, Cai B.

Int J Pharm. 2007 Aug 1;340(1-2):29-33. Epub 2007 Mar 12.

PMID:
17446016
4.

Preparation, characterization, biodistribution and antitumor efficacy of hydroxycamptothecin nanosuspensions.

Han M, Liu X, Guo Y, Wang Y, Wang X.

Int J Pharm. 2013 Oct 15;455(1-2):85-92. doi: 10.1016/j.ijpharm.2013.07.056. Epub 2013 Aug 5.

PMID:
23928147
5.

Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles.

Yang L, Cui F, Cun D, Tao A, Shi K, Lin W.

Int J Pharm. 2007 Aug 1;340(1-2):163-72. Epub 2007 Mar 25.

PMID:
17482779
7.

Modified hydrolysis kinetics of the active lactone moiety of 10-hydroxycamptothecin by liposomal encapsulation.

Shi K, Tian Y, Jiang Y, Wang L, Cui F.

Pharm Dev Technol. 2010 Dec;15(6):644-52. doi: 10.3109/10837450903426526. Epub 2009 Nov 27.

PMID:
19943738
8.

[Distribution of hydroxycamptothecin after aerosol inhalation in rabbits].

Chen J, Fang Y, Zhang HX, Huang LL, Qian XP, Liu BR.

Yao Xue Xue Bao. 2004 Sep;39(9):747-51. Chinese.

PMID:
15606028
9.
10.

Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions.

Zhao YX, Hua HY, Chang M, Liu WJ, Zhao Y, Liu HM.

Int J Pharm. 2010 Jun 15;392(1-2):64-71. doi: 10.1016/j.ijpharm.2010.03.027. Epub 2010 Mar 17.

PMID:
20302926
11.

High Drug Payload 10-Hydroxycamptothecin Nanosuspensions Stabilized by Cholesterol-PEG: In Vitro and In Vivo Investigation.

Yang L, Jiang J, Hong J, Di J, Liao Y, Kuang H, Wang X.

J Biomed Nanotechnol. 2015 Apr;11(4):711-21.

PMID:
26310077
12.

Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.

Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W.

Int J Pharm. 2008 May 1;355(1-2):321-7. doi: 10.1016/j.ijpharm.2007.12.016. Epub 2007 Dec 23.

PMID:
18242896
13.

[Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles].

Yang FY, Zhang WP, Chen HL, Fu Y, Wang XY, Wei SJ, Yang XY, Zhang YX, Dang HW.

Yao Xue Xue Bao. 2013 Jun;48(6):940-5. Chinese.

PMID:
23984532
14.

In-vivo pharmacokinetics, tissue distribution and anti-tumour effect of hydroxycamptothecin delivered in oil-in-water submicron emulsions.

Zhao YX, Liu DX, Liang WQ, Ye ZW.

J Pharm Pharmacol. 2012 Jun;64(6):783-91. doi: 10.1111/j.2042-7158.2012.01484.x. Epub 2012 Apr 25.

PMID:
22571256
15.

[Pharmacokinetic study of intraperitoneal chemotherapy with HCPT].

Ye M, Lin XX, Pan HM, Li N, Lou F, Jin W, Zheng Y, Wu JM.

Zhongguo Zhong Yao Za Zhi. 2005 Oct;30(20):1610-2. Chinese.

PMID:
16422545
16.

Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.

Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S.

Eur J Pharm Sci. 2009 Mar 2;36(4-5):580-90. doi: 10.1016/j.ejps.2008.12.005. Epub 2008 Dec 24.

PMID:
19135530
17.
18.

[Pharmaceutical evaluation of hydroxycamptothecin nanosuspensions with the action of inhibiting P-gp].

Pu XH, Sun J, Qin YM, Zhang X, Zhang P, He ZG.

Yao Xue Xue Bao. 2011 Jul;46(7):834-8. Chinese.

PMID:
22010354
19.

9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats.

Dadashzadeh S, Derakhshandeh K, Shirazi FH.

Anticancer Drugs. 2008 Sep;19(8):805-11. doi: 10.1097/CAD.0b013e3283099e5c.

PMID:
18690092
20.

Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin.

Kunii R, Onishi H, Machida Y.

Eur J Pharm Biopharm. 2007 Aug;67(1):9-17. Epub 2007 Jan 28.

PMID:
17337172
Items per page

Supplemental Content

Write to the Help Desk